Flamel Technologies (NASDAQ: FLML) today announced its financial results for the fourth quarter and year ended December 31, 2010. Fourth Quarter and Recent Highlights:
- Flamel received €3 million after achieving its first clinical milestone with Merck Serono for the development of an extended-release formulation of interferon beta 1-a.
- The Company announced receipt of a further €1 million payment following certain technical achievements requested by Merck Serono.
- Flamel and GSK are in negotiations for a new supply agreement for Coreg CR following the expiration of the old supply agreement on December 31, 2010; Flamel expects that these will be successful.
Total costs and expenses during the fourth quarter declined to $11.4 million versus $16.5 million in the year-ago period. Costs of goods and services sold were $1.9 million in the fourth quarter of 2010 versus $3.6 million in the year-ago period. Research and development costs in the fourth quarter of 2010 totaled $6.9 million versus $9.0 million in the year-ago period. Selling, general, and administrative costs were $2.7 million in the fourth quarter 2010 versus $4.0 million in the fourth quarter of 2009.Net income for the fourth quarter of 2010 was $2.7 million versus a net loss of ($5.7 million) in the year-ago period. Net income per share (basic and diluted) was $0.11 versus a net loss per share (basic) of ($0.23) in the fourth quarter of 2009. Flamel’s 2010 Annual Results For the calendar year 2010, Flamel reported total revenues of $37.1 million, compared to $42.1 million in 2009. License and research revenue during 2010 was $19.7 million versus $20.8 million in 2009. Product sales and services for the year 2010 were $8.2 million, compared to $11.9 million in the year-ago period. Other revenues, consisting primarily of royalty income from sales of Coreg CR by GSK, totaled $9.2 million in 2010 versus $9.4 million in 2009. Total costs and expenses declined in 2010 to $47.0 million from $53.9 million in 2009. Costs of goods and services sold were $6.9 million in 2010 versus $10.1 million in 2009. Research & development expenses were $28.7 million versus $30.4 million in 2009. SG&A in 2010 totaled $11.3 million versus $13.3 million in 2009. The Company reported a net loss for the year 2010 of ($9.0 million) or ($0.37) per share versus a net loss in 2009 of ($11.4 million), or ($0.47) per share. Flamel finished 2010 with $31.3 million in cash and marketable securities.
About Flamel TechnologiesFlamel Technologies is a drug delivery company with two intellectual property platforms: Micropump, for the controlled release of drugs best absorbed in the small intestine; and Medusa, for the controlled release of proteins, peptides, and other molecules injected subcutaneously or administered intravenously. Both of these platforms offer potential advantages with respect to efficacy and the reduction of side-effects, in addition to the obvious benefits associated with more convenient dosing regimens. For detailed company information, including copies of this and other press releases, see Flamel’s web site: www.flamel.com. A conference call to discuss these results is scheduled for 8:30 AM Eastern Standard Time, March 4, 2011. The dial-in number is: 1-800-581-5838 (Conference ID number: 8906309). International callers are invited to dial-in + 1 719-325-2159. This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The document reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. We undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise. You should not place undue reliance on these forward-looking statements. For further information on the Company, please review Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2009.
|Condensed Consolidated Statements of Operations|
|(amounts in thousands, except per share data)|
|Three months ended December 31,||Twelve months ended December 31,|
|License and research revenue||$4,659||$8,839||$20,815||$19,704|
|Product sales and services||4,269||2,210||11,871||8,180|
|Costs and expenses:|
|Cost of goods and services sold||(3,610)||(1,869)||(10,118)||(6,914)|
|Research and development||(8,952)||(6,863)||(30,416)||(28,687)|
|Selling, general and administrative||(3,966)||(2,674)||(13,337)||(11,333)|
|Profit (loss) from operations||(5,937)||2,045||(11,753)||(9,840)|
|Interest income net||76||114||425||440|
|Foreign exchange gain (loss)||205||196||(83)||109|
|Other income (loss)||(41)||432||(28)||525|
|Income (loss) before income taxes||(5,697)||2,787||(11,439)||(8,766)|
|Income tax expense||-||(109)||-||(209)|
|Net Income (loss)||($5,697)||$2,678||($11,439)||($8,975)|
|Earnings (loss) per share|
|Basic earnings (loss) per ordinary share||($0.23)||$0.11||($0.47)||($0.37)|
|Diluted earnings (loss) per share||($0.23)||$0.11||($0.47)||($0.37)|
|Weighted average number of shares outstanding (in thousands) :|